Transatlantic personalised medicines alliance formed
Two global leaders in personalised medicines technology – Horizon Discovery in the UK and Transgenomic Inc in the US – have formed an alliance to power advances. The collaboration aims to develop improved genetic diagnostic tests incorporating state of the art controls.
The partnership will enable Transgenomic to transition from the use of plasmid-derived controls to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays – and for any new assays developed in future.
Horizon provides research tools to support translational genomics and the development of personalised medicines. Transgenomic, Inc, based in Omaha, Nebraska, is a global biotechnology company advancing personalised medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services.
Horizon will provide its renewable, genetically defined Quantitative Molecular Reference Standards in both gDNA (genomic DNA) and FFPE (formalin fixed paraffin embedded) format, via its Horizon Diagnostics division.
The Quantitative Molecular Reference Standards will be used as advanced reference standards for Transgenomic’s range of genetic diagnostic tests, and in the development of novel tests and in vitro diagnostic testing kits. The products will be chosen from Horizon Diagnostics’ existing inventory of over 300 products; Horizon’s GENESIS™ gene editing platform will also be employed to precisely engineer new lines as needed, to support the development of the new tests and kits.
“Transgenomic operates at the cutting edge of molecular diagnostics and is an ideal partner for Horizon,” said Paul Morrill, senior VP of Horizon Diagnostics.
“This collaboration adds to our strong network of world class partners practicing high quality science, and contributes to our goal of advancing personalised medicine and ultimately better patient care.”
• PHOTOGRAPH SHOWS: Paul Morrill